← Back to searchRecruitingRecruiting
Safety and Feasibility of Tele-supervised Home-based Transcranial Direct Current Stimulation in Parkinson's Disease
NCT06804668 · Brigham and Women's Hospital
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
The goal of this clinical trial is to learn whether home-based transcranial direct current stimulation (tDCS) is safe and practical for people aged 40 to 70 years with Parkinson's Disease. The study aims to find out if participants can use the tDCS device at home without serious side effects and whether it is easy for them to use on their own.
Participants will first attend an in-person visit to learn how to use the tDCS device. They will then use the device at home once a day for 20 minutes over seven consecutive days. Video calls on days 2 and 3 will provide support and supervision. After each session, participants will complete brief online questionnaires about any side effects and how easy the device was to use. The study will also check if using tDCS at home improves motor symptoms in Parkinson's Disease by using a standard movement assessment.
Eligibility criteria
Inclusion Criteria:
* Patients with the diagnosis of Parkinson's disease, aged between 40 and 70, who provide verbal and written informed consent will be included. Patients should have access to a computer system for video calls and completing the questionnaires, and they must be able to use it.
Exclusion Criteria:
* Psychiatric symptoms such as moderate or severe depression
* Cranial metal implants
* Cardiac pacemaker
* Epilepsy, stroke
* Substance abuse
* Inability to adjust the neoprene cap with the electrodes independently due to movement disturbances
Study design
Enrollment target: 6 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-02-06
Estimated completion: 2026-09-01
Last updated: 2026-01-02
Interventions
Device: tDCS
Primary outcomes
- • Feasibility of repeated network-targeted multifocal tDCS at home (8 days.)
Sponsor
Brigham and Women's Hospital · other
Contacts & investigators
ContactLeila Montaser Kouhsari, MD, PhD · contact · lmontaser@bwh.harvard.edu · (617) 732-7547
InvestigatorMichael D Fox, MD, PhD · principal_investigator, Center for Brain Circuit Therapeutics, Department of Neurology, Brigham & Women's Hospital, Boston, MA
All locations (1)
Center for Brain Circuit Therapeutics, Department of Neurology, Brigham & Women's HospitalRecruiting
Boston, Massachusetts, United States